- Companies
- Talkiatry
Talkiatry Funding, Investors & Competitors
Talkiatry has raised $452M across 5 funding rounds, most recently a $210M Series D in February 2026.
Last Talkiatry funding round
$210M
Series D · Feb 2026
Cumulative funding Talkiatry raised
$452M
across 5 funding rounds
Key investors in Talkiatry
Left Lane Capital
Andreessen Horowitz
Perceptive Advisors
Blisce
Sofina
Relevance Ventures
Cold Start Ventures
GreyMatter
About Talkiatry
Talkiatry is a virtual psychiatry provider offering in-network services through over 300 licensed psychiatrists. It delivers evaluations, diagnoses, treatment plans, and medication management for conditions including anxiety, depression, ADHD, and substance use disorders.
Founded
2019
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Services
Talkiatry Funding History
Talkiatry has raised a total of $452M across 5 funding rounds.
Talkiatry's first fundraising round was a $20M Series A in July 2021. The most recent completed round was a $210M Series D in February 2026.
Talkiatry funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Feb 2026 | Series D | Perceptive Advisors (lead); Left Lane Capital; Andreessen Horowitz; Sofina; Blisce | $210M | Talkiatry, a full-stack telepsychiatry provider, raised an oversubscribed $210 million Series D funding round on February 12, 2026, led by Perceptive Advisors with participation from Sofina, Andreessen Horowitz (a16z), blisce/, and Left Lane Capital, plus a debt facility from Banc of California, bringing total funding to over $400 million. The company employs over 800 full-time W2 psychiatrists and 300 therapists, delivering 3 million patient visits to date, and positions itself as the nation's largest private employer of psychiatrists. It operates in 45 states, is in-network with over 100 insurers covering 170 million lives, and partners with 50+ health systems via its Mindshare Partner Program to serve as an outsourced psychiatry department. Talkiatry's model emphasizes employed clinicians, proprietary AI-powered technology for back-office automation, patient engagement, and clinical support, and insurance-covered virtual visits for conditions like anxiety, depression, bipolar disorder, OCD, PTSD, and postpartum depression. Clinical outcomes include 87% of anxiety patients and 86% of depression patients showing symptom improvement after two visits, 60% lower dropout rates than industry benchmarks, 76 NPS rating, and 22% higher therapeutic alliance ratings. The company reports payer savings of up to $700 per member per month through reduced emergency visits and admissions, with no subscription models or pharmacy affiliations. The funding will fuel expansion across acuity spectrum, technology investments including AI to reduce clinician burnout by 80%, and scaling as the in-network psychiatry partner for health systems, payers, and employers. Talkiatry was ranked on Deloitte Technology Fast 500 in 2025 and recognized by Fortune and Great Place to Work. CEO Robert Krayn stated no imminent IPO plans, focusing on enterprise-scale operations; the company declined to disclose valuation or profitability progress. |
| Jun 2024 | Series C | Andreessen Horowitz (lead); Perceptive Advisors | $130M | Talkiatry is a New York City-based telepsychiatry provider founded in 2020 that delivers high-quality, in-network psychiatric care for conditions including ADHD, anxiety, bipolar disorder, depression, OCD, and PTSD to children and adults across 43 states. The company employs over 300 full-time W-2 psychiatrists, distinguishing it from peers that often use contractors, and partners with more than 60 health plans such as UnitedHealthcare, Aetna, Blue Cross Blue Shield, Cigna, and Humana, providing access to over 70% of commercially insured individuals. It has delivered over one million patient visits, with published data showing clinically significant improvements in depression and anxiety symptoms. On June 18, 2024, Talkiatry announced a $130 million Series C funding round comprising equity and debt to expand its value-based care model, scale operations, reduce total cost of care, improve health outcomes, and pursue growth including potential acquisitions and an eventual IPO. The equity portion was led by Andreessen Horowitz (a16z) with participation from Perceptive Advisors, and debt financing came from Banc of California. This brings Talkiatry's total funding to $245 million, following a $75 million Series B in September 2023 and prior investments from Left Lane Capital and blisce. Talkiatry demonstrates strong outcomes in value-based arrangements, including a 68% reduction in patient hospitalizations, 32% fewer emergency room visits, and $700 in monthly savings per member on total cost of care compared to peers for a leading national health plan cohort. Andreessen Horowitz highlighted Talkiatry's ability to mainstream outcomes-based psychiatric care and risk-based payment models through affordable, high-quality treatment and expanding payer partnerships. The company integrates with electronic health records for referrals and focuses on underserved populations while positioning for broader adoption of value-based behavioral health care amid ongoing telemental health deal activity. |
| Jul 2022 | Series B | Blisce (lead); Yousif Al-Dujaili; Left Lane Capital; Transform Capital; GreyMatter | $75M | - |
| Jan 2022 | Series A | Left Lane Capital (lead) | $17M | - |
| Jul 2021 | Series A | Left Lane Capital (lead); Cold Start Ventures; Relevance Ventures; Richard Park | $20M | Talkiatry raised $20 million in a Series A funding round announced around July 28, 2021, comprising an initial $5 million led by Sikwoo Capital Partners (announced earlier in February 2021) and an additional $15 million led by Left Lane Capital, with participation from Relevance Ventures and Dr. Richard Park, founder and former CEO of CityMD. The funding aimed to build out its proprietary technology platform and expand its geographic footprint into additional states in the Northeast, Mid-Atlantic, and South starting in 2022. Founded in 2020 by Robert Krayn and Dr. Georgia Gaveras, Talkiatry operates as an in-network psychiatric care provider offering both in-person and virtual mental health services, employing psychiatrists and using a technology-driven model to address psychiatrist shortages while meeting insurer requirements. At the time of the Series A, Talkiatry employed more than 30 psychiatrists and 40 total providers, having completed over 30,000 patient visits since launch. The company had partnered with major insurers including UnitedHealthcare, Aetna, Humana, Cigna, and Blue Cross Blue Shield, positioning it to provide accessible care without out-of-pocket costs beyond typical copays. Its model emphasizes ongoing care, starting with virtual surveys for matching patients to psychiatrists, followed by diagnosis, therapy, medication management, and tools like VR. Talkiatry differentiates itself in the behavioral health space by focusing exclusively on in-network psychiatry services, competing with platforms like Cerebral, Headway, and Uplift, while contrasting with better-capitalized players like Ginger and Lyra Health. |
Who has invested in Talkiatry?
11 investors have backed Talkiatry across its funding rounds, including Left Lane Capital, Andreessen Horowitz, Perceptive Advisors, Blisce, Sofina and Relevance Ventures.
Lead investors include Perceptive Advisors, Andreessen Horowitz, Blisce and Left Lane Capital.
Talkiatry Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Jul 2021 | ||
| 2 | Lead | Jun 2024 | ||
| 2 | Lead | Jun 2024 | ||
| 2 | Lead | Jul 2022 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Jul 2022 | ||
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Jul 2022 | ||
This data is available for Pro users. Sign up to see all 11 Talkiatry investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialTalkiatry Competitors
Talkiatry competitors include listed companies like Hims and Teladoc, and private ones like Cerebral, Grow Therapy, Headway and Nourish.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $2.3B | $178M | $6.5B | 2.4x | ||
| Private | - | - | $4.8B | - | ||
| Private | $1B | - | $3B | - | ||
| Private | - | - | $2.3B | - | ||
| Private | $160M | - | $1.8B | 10.9x | ||
| Publicly listed | $2.5B | $124M | $1.1B | 0.6x |
Talkiatry Public Comps
Talkiatry is still privately-owned, but its public comps include Humana Inc., Max Healthcare Institute, Oscar Health, Hims, Doximity, ACADIA Pharmaceuticals, Compass Pathways, Ping An Healthcare, JMDC and GoodRx.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $130B | $3B | 0.4x | 0.3x | 17.8x | 16.6x | |||
| $858M | $232M | 12.6x | 10.2x | 46.5x | 36.8x | |||
| $12B | ($391M) | 0.5x | 0.4x | (15.9x) | 12.8x | |||
| $2.3B | $178M | 3.1x | 2.4x | 40.4x | 23.9x | |||
| $645M | $229M | 6.3x | 6.2x | 17.7x | 11.9x | |||
| $1.1B | $119M | 3.6x | 3.2x | 32.3x | 33.6x | |||
| - | ($293M) | - | - | (5.8x) | (8.4x) | |||
| $815M | $52M | 0.9x | 0.9x | 13.4x | 16.9x | |||
This data is available for Pro users. Sign up to see all Talkiatry competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Talkiatry
| When was Talkiatry founded? | Talkiatry was founded in 2019. |
| Where is Talkiatry headquartered? | Talkiatry is headquartered in New York City, NY, United States. |
| Is Talkiatry publicly listed? | No, Talkiatry is a private, VC-backed company. |
| How much funding has Talkiatry raised? | Talkiatry has raised $452M across 5 funding rounds. |
| What was Talkiatry's last funding round? | Talkiatry's last funding round was a $210M Series D in February 2026, led by Perceptive Advisors. |
| Who are Talkiatry's investors? | Talkiatry's investors include Left Lane Capital, Andreessen Horowitz, Perceptive Advisors, Blisce, Cold Start Ventures, Relevance Ventures, Yousif Al-Dujaili, Richard Park, Transform Capital, Sofina and 1 other. |
| Which companies are comparable to Talkiatry? | Companies comparable to Talkiatry include Hims, Cerebral, Grow Therapy, Headway, Nourish and Teladoc. |
See companies similar to Talkiatry
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




